Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814173 | 0.84 | DAO (0.65) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL2176203 | 0.84 | PARP1 (0.47) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL23202358 | 0.83 | DAO (0.50) | DAOCA12CA1CA2CA7 | |
| SCHEMBL12407032 | 0.82 | LOXL2 (0.49) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL24036135 | 0.82 | PARP1 (0.49) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL24459408 | 0.82 | PARP1 (0.46) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL2173402 | 0.82 | PARP1 (0.46) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL16355881 | 0.81 | DAO (0.41) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL2332640 | 0.81 | PARP1 (0.45) | PARP1DAOCA12CA1CA2 | |
| SCHEMBL10673042 | 0.81 | USP2 (0.47) | PARP1DAOCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110099907-A | The Thienopyrroles derivative of targeting protein, composition, method and application thereof | 拜欧赛里克斯公司 | 2019-08-06 | — | — | CN | disclosed |
| US-9415027-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9415027-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9415027-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150258048-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150258048-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150258048-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9051294-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051294-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051294-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| WO-2011013624-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | キッセイ薬品工業株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
| US-7589213-B2 | Therapeutic substituted lactams | OLD DAVID W | 2009-09-15 | — | — | US | disclosed |
| US-7589213-B2 | Therapeutic substituted lactams | OLD DAVID W | 2009-09-15 | — | — | US | disclosed |
| US-20080269498-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269498-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2008-10-30 | — | — | US | disclosed |
| US-5786379-A | Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-07-28 | — | — | US | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269498-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | MRPL21, CLPP, PEPD | PARP1 943/4885DAO 174/4885CA12 2206/4885 |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, ARRB1 | PARP1 1686/4885DAO 3548/4885CA12 2525/4885 |
| US-20150258048-A1 | THERAPEUTIC AGENTS | PTGER4, PTGER2, PTGER1 | PARP1 668/4885DAO 4300/4885CA12 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.